Description Anti-lymphotoxin alpha (LTa) is a humanized monoclonal antibody that binds to and is designed to neutralize the activities of secreted homotrimeric LTa3 and membrane bound heterotrimer LTa1/β2. Anti-LTa can also deplete pathogenic T cells that are implicated in autoimmune diseases.
Development Status A Phase II clinical trial evaluating Anti-LT alpha for rheumatoid arthritis is ongoing.
Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.
National Institutes of Health Website: www.clinicaltrials.gov
November 2010